GEN-MKT-18-7897-A
Apr 16, 2019 | Blogs, Technology | 0 comments
Every decision you make requires a number
As a pharmaceutical scientist, you understand the challenges in getting a new drug through the discovery and development pipeline. As an innovation partner in mass spectrometry, SCIEX works continuously with you, our customers, to provide solutions that meet those challenges. Our focus is on getting you the numbers you need to make informed decisions.
Working with complex sample matrices, you need technology that allows you to see everything in your sample, no matter how high or low the levels. Tools that can detect low pg/mL levels (or lower) can analyze a wide mass range of compounds (across five orders of magnitude) and can resolve similar or even isobaric compounds, enable you to get the quality data that allow your lab to move forward. And you need to move quickly, without wasting time on repairs and troubleshooting.
Conquering your challenges
Since the first commercially available electrospray triple-quadrupole instrument, SCIEX has delivered innovative mass spectrometry-based solutions. Today, we continue that legacy of innovation and our commitment to delivering the technology you need to move past the challenges that slow you down.
As we mark the 30th anniversary of the industry-changing API III LC-MS/MS system in 2019, we are revisiting the basics of answering: Why quant? Why SCIEX for quant?? We‘ll examine how our mass spectrometry innovation addresses the challenges you struggle with the most, today– exploring what you need from the technology that helps you achieve your goals. Now, let’s talk a little bit about the four key pillars we use to characterize those goals: Sensitivity, Selectivity, Reproducibility, and Robustness.
SensitivityYou need a mass spectrometer that sees what’s in your sample. Superior sensitivity is a tool for the situations you face every day:
Read the blog, ‘Sensitivity, It’s at the Very Heart of Who We Are’ >
SelectivityPowerful selectivity keeps your target compounds from being obscured by unexpected interferences:
Read the blog, ‘Detect the Signal, Not the Noise’ >
ReproducibilityIndustry leaders discuss their results clearly and with confidence. Knowing you’re presenting reproducible data makes those discussions easier:
Read the blog, ‘Improving Precision’ >
RobustnessDowntime costs money and keeps you from getting to market on time. A robust system helps solve that problem:
Read the blog, ‘Robust by Design. Built-in.’ >
To see how SCIEX technology innovations impact pharmaceutical analysis, explore the applications and techniques in our ebook.
Finding the right information shouldn’t slow you down. Whether you’re troubleshooting your mass spec, learning something new, or optimizing performance, access to the right resources at the right moment makes all the difference.
As an analytical strategy, middle-down mass spectrometry (MS) workflows characterize biotherapeutic proteins by analyzing large, digested protein fragments or defined subunits, rather than fully intact proteins (top-down) or digested peptides (bottom-up). A middle-down strategy combines the strengths of top-down and bottom-up approaches by delivering high sequence coverage and structural specificity while maintaining relatively simple sample preparation. In practice, middle-down analysis enables accurate mass measurement, rapid sequence confirmation, and localization of key post-translational modifications (PTMs) on protein subunits that are directly relevant to product quality.
In biopharmaceutical development, sequence variants (SV) are considered an inherent risk of producing complex proteins in living systems. Sequence variants are unintended changes to the amino acid sequence of a biotherapeutic and can be caused by errors in transcription or translation in the host cell, or cell culture and process conditions. Detailed analysis of SVs is important in process and product development to ensure the drug’s safety and efficacy. Even low‑level sequence variants can have significant implications for product quality, safety, and efficacy, making their accurate detection and characterization a critical requirement across development, process optimization, and regulatory submission.
Posted by
You must be logged in to post a comment.
Share this post with your network